Event to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel, Nov. 28, 2023 (GLOBE NEWSWIRE) Sol-Gel Technologies, Ltd. (Nasdaq: SLGL) (“Sol-Gel”), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin conditions, and with two approved large-category dermatology products, TWYNEO
"Gorlin Syndrome Market"DelveInsight's "Gorlin Syndrome Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Gorlin Syndrome, historical and forecasted epidemiology as
Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Get Free Report) saw a significant increase in short interest in the month of October. As of October 15th, there was short interest totalling 59,200 shares, an increase of 16.5% from the September 30th total of 50,800 shares. Based on an average daily volume of 10,400 shares, the short-interest ratio […]
Sol-Gel Technologies Ltd. (NASDAQ:SLGL – Free Report) – HC Wainwright lifted their Q3 2023 earnings per share (EPS) estimates for shares of Sol-Gel Technologies in a report released on Monday, August 14th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings of ($0.24) per share for the quarter, up from their […]